First Hawaiian Bank lowered its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 0.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,953 shares of the biopharmaceutical company’s stock after selling 21 shares during the period. First Hawaiian Bank’s holdings in Bristol-Myers Squibb Company were worth $324,000 at the end of the most recent reporting period.
Several other large investors have also bought and sold shares of BMY. State Street Corp raised its stake in Bristol-Myers Squibb Company by 3.8% in the fourth quarter. State Street Corp now owns 67,670,322 shares of the biopharmaceutical company’s stock worth $3,954,652,000 after buying an additional 2,470,257 shares in the last quarter. Dodge & Cox purchased a new stake in shares of Bristol-Myers Squibb Company during the fourth quarter worth about $1,316,815,000. Norges Bank purchased a new stake in shares of Bristol-Myers Squibb Company during the fourth quarter worth about $770,318,000. Teachers Advisors LLC increased its stake in shares of Bristol-Myers Squibb Company by 10.8% in the fourth quarter. Teachers Advisors LLC now owns 3,824,604 shares of the biopharmaceutical company’s stock worth $223,510,000 after buying an additional 371,391 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Bristol-Myers Squibb Company by 5.6% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 3,685,856 shares of the biopharmaceutical company’s stock worth $198,741,000 after buying an additional 195,892 shares during the last quarter. Institutional investors own 69.75% of the company’s stock.
Shares of Bristol-Myers Squibb Company (NYSE:BMY) traded up 1.40% on Monday, reaching $55.22. 6,209,903 shares of the company’s stock traded hands. The firm has a market capitalization of $90.97 billion, a P/E ratio of 19.18 and a beta of 1.19. Bristol-Myers Squibb Company has a 52 week low of $46.01 and a 52 week high of $77.12. The firm’s 50 day moving average is $54.40 and its 200 day moving average is $55.01. Bristol-Myers Squibb Company also was the target of some unusual options trading on Friday. Traders bought 17,932 call options on the company. This is an increase of approximately 100% compared to the average volume of 8,963 call options.
Bristol-Myers Squibb Company (NYSE:BMY) last released its earnings results on Thursday, April 27th. The biopharmaceutical company reported $0.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.72 by $0.12. Bristol-Myers Squibb Company had a return on equity of 31.86% and a net margin of 24.22%. The firm had revenue of $4.93 billion for the quarter, compared to the consensus estimate of $4.75 billion. During the same period in the prior year, the business posted $0.74 earnings per share. The firm’s revenue for the quarter was up 12.3% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb Company will post $2.95 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, August 1st. Investors of record on Friday, July 7th will be given a dividend of $0.39 per share. The ex-dividend date is Wednesday, July 5th. This represents a $1.56 annualized dividend and a yield of 2.83%. Bristol-Myers Squibb Company’s dividend payout ratio (DPR) is presently 54.17%.
ILLEGAL ACTIVITY NOTICE: This report was first published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://baseballnewssource.com/markets/bristol-myers-squibb-co-bmy-shares-sold-by-first-hawaiian-bank-updated-updated/862600.html.
A number of analysts recently commented on the stock. BidaskClub upgraded shares of Bristol-Myers Squibb Company from a “sell” rating to a “hold” rating in a research note on Saturday, June 10th. Vetr upgraded shares of Bristol-Myers Squibb Company from a “buy” rating to a “strong-buy” rating and set a $58.88 target price on the stock in a research note on Monday, June 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $64.00 target price on shares of Bristol-Myers Squibb Company in a research note on Monday, June 5th. BMO Capital Markets cut shares of Bristol-Myers Squibb Company from a “market perform” rating to an “underperform” rating and set a $47.00 price objective on the stock. in a research report on Wednesday, May 3rd. Finally, Robert W. Baird initiated coverage on shares of Bristol-Myers Squibb Company in a report on Tuesday, April 25th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $62.41.
In other news, Director Lamberto Andreotti sold 34,000 shares of the firm’s stock in a transaction dated Tuesday, March 28th. The stock was sold at an average price of $56.17, for a total value of $1,909,780.00. Following the transaction, the director now directly owns 986,112 shares in the company, valued at approximately $55,389,911.04. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 85,000 shares of company stock worth $4,675,000 over the last quarter. 0.23% of the stock is currently owned by company insiders.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with our FREE daily email newsletter.